Director of molecular diagnostics, Tianjin Cancer Hospital Center in JinPu said, genetic testing is through the blood, other body fluids or tumor tissue for gene sequences were detected and analyzed. Currently, breast cancer topped the incidence of female cancer, and lung cancer is the first cancer mortality rates for men and women, the incidence increased year by year, and getting younger and younger.
Breast cancer risk population genetic screening technique to detect only need to be provided by 5 ml of peripheral blood, can breast cancer susceptibility gene for six full-exon gene mutation, according to susceptibility gene mutation, gene mutation carriers to assess chance of developing breast cancer, pursuant to adopt appropriate preventive measures, so as to achieve the purpose of early prevention of breast cancer.
Lung cancer genetic testing, is the use of lung cancer patients, "green beans" the size of a tissue sample, using next-generation sequencing technology, the 14 genes in lung cancer hotspot areas driven deep sequencing to detect gene mutations drive, and as a basis to optimize the development of individualized cancer targeted drug treatment programs, thus promoting individual treatment of lung cancer.
Clinical director of the National Cancer Research Center, Tianjin Cancer Institute director Hao Xishan academician said of tumor molecular diagnostics and gene detection platform built technology, is an important way to achieve tumor control and patient personalized medicine, will bring two The major change, one individual targeted therapy, the second is the prevention of diseases that may occur.
According to test results carried out a risk assessment of clinical intervention
With respect to lung cancer genetic testing technology, focusing on the prevention of breast cancer in high-risk populations by genetic screening technology more public attention. So, what populations are